Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 27;2014(11):CD006938.
doi: 10.1002/14651858.CD006938.pub3.

Droperidol for treatment of nausea and vomiting in palliative care patients

Jemma Storrar  1 , Morwenna Hitchens, Tracey Platt, Saskie Dorman
Affiliations

Droperidol for treatment of nausea and vomiting in palliative care patients

Jemma Storrar et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an updated version of the original Cochrane review published in Issue 10, 2010, on droperidol for the treatment of nausea and vomiting in palliative care patients. Nausea and vomiting are common symptoms in patients with terminal illness and can be very unpleasant and distressing. There are several different types of antiemetic treatments that can be used to control these symptoms. Droperidol is an antipsychotic drug and has been used and studied as an antiemetic in the management of postoperative and chemotherapy nausea and vomiting.

Objectives: To evaluate the efficacy and adverse events (both minor and serious) associated with the use of droperidol for the treatment of nausea and vomiting in palliative care patients.

Search methods: We searched electronic databases including CENTRAL, MEDLINE (1950-), EMBASE (1980-), CINAHL (1981-) and AMED (1985-), using relevant search terms and synonyms. The basic search strategy was ("droperidol" OR "butyrophenone") AND ("nausea" OR "vomiting"), modified for each database. We updated the search on 2 December 2009. We performed updated searches of MEDLINE, EMBASE, CENTRAL and AMED 2009 to 2013 on 19 November 2013 and of CINAHL on 20 November 2013. We also searched trial registers (metaRegister of controlled trials (www.controlled-trials.com/mrct), clinicaltrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/)) on 22 November 2013, using the keyword "droperidol".

Selection criteria: Randomised controlled trials (RCTs) of droperidol for the treatment of nausea or vomiting, or both, in adults receiving palliative care or suffering from an incurable progressive medical condition.

Data collection and analysis: We judged the potential relevance of studies based on their titles and abstracts, and obtained studies that we anticipated might meet the inclusion criteria. Two review authors independently reviewed the abstracts for the initial review and four review authors reviewed the abstracts for the update to assess suitability for inclusion. We discussed discrepancies to achieve consensus.

Main results: The 2010 search strategy identified 1664 abstracts (and 827 duplicates) of which we obtained 23 studies in full as potentially meeting the inclusion criteria. On review of the full papers, we identified no studies that met the inclusion criteria.The updated searches carried out in November 2013 identified 304 abstracts (261 excluding duplicates) of which we obtained 18 references in full as potentially meeting the inclusion criteria. On review of the full papers, we identified no studies that met the inclusion criteria, therefore there were no included studies in this review.We found no registered trials of droperidol for the management of nausea or vomiting in palliative care.

Authors' conclusions: Since first publication of this review, no new studies were found. There is insufficient evidence to advise on the use of droperidol for the management of nausea and vomiting in palliative care. Studies of antiemetics in palliative care settings are needed to identify which agents are most effective, with minimum side effects.

PubMed Disclaimer

Conflict of interest statement

JS: None known.

MH: None known.

TP: None known.

SD: None known.

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

References

References to studies excluded from this review

Aapro 1991 {published data only}
    1. Aapro MS, Froidevaux P, Roth A, Alberto P. Antiemetic efficacy of droperidol or metoclopramide combined with dexamethasone and diphenhydramine. Oncology 1991;48:116-20. - PubMed
Aldrete 1995 {published data only}
    1. Aldrete J. Reduction of nausea and vomiting from epidural opioids by adding droperidol to the infusate in home-bound patients. Journal of Pain and Symptom Management 1995;10(7):544-7. - PubMed
Braude 2006 {published data only}
    1. Braude D, Soliz T, Crandall C, Hendey G, Andrews J, Weichental L. Antiemetics in the ED: a randomized controlled trial comparing 3 common agents. American Journal of Emergency Medicine 2006;24:177-82. - PubMed
Casey 2011 {published data only}
    1. Casey C, Chen LM, Rabow MW. Symptom management in gynaecologic malignancies. Expert Review of Anticancer Therapy 2011;11(7):1077-89. - PubMed
Cheung 2011 {published data only}
    1. Cheung WY, Zimmermann C. Pharmacologic management of cancer-related pain, dyspnea and nausea. Seminars in Oncology 2011;38(3):450-9. - PubMed
Dale 2011 {published data only}
    1. Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative Pain Guidelines: Opioid switching to improve analgesia or reduce side effects. A systematic review. Palliative Medicine 2011;25(5):494-503. - PubMed
Etievant 2010 {published data only}
    1. Etievant A, Betry C, Haddjeri N. Partial dopamine D2 / serotonin 5HT-1a receptor agonists as new therapeutic agents. Open Neuropsychopharmacology 2010;3:1-12.
Feyer 2011 {published data only}
    1. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Annals of Oncology 2011;22(1):30-8. - PubMed
Fujii 1987 {published data only}
    1. Fujii M, Kiura K, Kamei H, Okabe K, Toki H. Antiemetic effects of combinations of metoclopramide, dexamethasone and dexamethasone for the prevention of cisplatin-induced gastrointestinal toxicity: a randomized crossover trial [Japanese]. Gan To Kagaku Ryoho 1987;14(7):2257-61. - PubMed
Getto 2011 {published data only}
    1. Getto L, Zeserson E, Breyer M. Vomiting, diarrhea, constipation and gastroenteritis. Emergency Medicine Clinics of North America 2011;29(2):211-37. - PMC - PubMed
Glare 2011 {published data only}
    1. Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clinical Interventions in Aging 2011;6(1):243-59. - PMC - PubMed
Gonzales 2011 {published data only}
    1. Gonzales MJ, Widera E. Nausea and other non-pain symptoms in long-term care. Clinics in Geriatric Medicine 2011;27(2):213-28. - PubMed
Hardy 2010 {published data only}
    1. Hardy JR, O'Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. Journal of Pain & Symptom Management 2010;40(1):111-6. - PubMed
Herrstedt 1991 {published data only}
    1. Herrstedt J, Hannibal J, Hallas J, Andersen E, Laursen LC, Hansen M. High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting. Annals of Oncology 1991;2:223-7. - PubMed
Jacobs 1980 {published data only}
    1. Jacobs AJ, Deppe G, Cohen CJ. A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotherapy with cis-platinum. Gynecologic Oncology 1980;10:55-7. - PubMed
Kim 1994 {published data only}
    1. Kim H, Rosenberg SA, Steinberg SM, Cole DJ, Weber JS. A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. Journals of Immunotherapy 1994;16:60-5. - PubMed
Lehoczky 2001 {published data only}
    1. Lehoczky O, Bagameri A, Sarosi Z, Kulcsar T, Pulay T. Does the addition of an anxiolytic drug improve the antiemetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting? [Fokozhato-e a szteroid es granisetron antiemeticus kombinacio hatekonysaga anxiolyticus szer hozzaadasaval a cisplatin okozta hanyas profilaxisaban?]. Orvosi Hetilap 2001;142:1681-4. - PubMed
Lennox 1985 {published data only}
    1. Lennox B, Reid M, McCaffrey D, Miaskowski C, Kaplan BH, Vogl SE. Randomized double-blind crossover trial of prochlorperazine (P) alone versus prochlorperazine plus droperidol (D) for emesis prophylaxis in patients (PTS) receiving intravenous bolus cis-platinum (DDP). Proceedings of American Association of Cancer Research 1985;26:189.
Lewis 1984 {published data only}
    1. Lewis GO, Bernath AM, Ellison NM, Gallagher JG, Porter PA, Rine KT. Double-blind crossover trial of droperidol, metoclopramide, and prochlorperazine as antiemetics in cisplatin therapy. Clinical Pharmacy 1984;3:618-21. - PubMed
McHugh 2011 {published data only}
    1. McHugh ME, Miller-Saultz D. Assessment and management of gastrointestinal symptoms in advanced illness. Primary Care - Clinics in Office Practice 2011;38(2):225-46. - PubMed
McNicol 2003 {published data only}
    1. McNicol A, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic non-cancer pain: a systematic review. Journal of Pain 2003;4(5):231-56. - PubMed
Melsom 1982 {published data only}
    1. Melsom H, Nandrup E, Monge OR. Metoclopramide (Primperan) versus droperidol (Dridol) as an antiemetic in intravenous cancer chemotherapy [Metoklopramid (Primperan) versus droperidol (Dridol) som antiemetikum ved intravenos cancerkjemoterapi]. Tidsskrift for Den Norske Laegeforening 1982;102(16):914-5. - PubMed
Minegishi 2003 {published data only}
    1. Minegishi Y, Ohmatsu H, Miyamoto T, Niho S, Goto K, Kubota K, et al. Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study. European Journal of Cancer 2004;40:1188-92. - PubMed
Muller 1989 {published data only}
    1. Muller G, Konig H. Antiemetic efficacy of high-dose metoclopramide and high-dose droperidol in preventing cisplatin-induced nausea and emesis: a single-blind comparison. Blut 1989;59(3):280.
Niijima 1986 {published data only}
    1. Niijima T, Isurugi K, Akaza H, Kondon Y, Kawabe K, Fujita K, et al. Randomised cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy [Japanese]. Gan To Kagaku Ryoho 1986;13(7):2376-82. - PubMed
O'Connor 2011 {published data only}
    1. O'Connor B, Creedon B. Pharmacological treatment of bowel obstruction in cancer patients. Expert Opinion on Pharmacotherapy 2011;12(14):2205-14. - PubMed
Owens 1984 {published data only}
    1. Owens NJ, Schauer AR, Nightingale CH, Golub GR, Martin RS, Williams HM, et al. Antiemetic efficacy of prochlorperazine, haloperidol, and droperidol in cisplatin-induced emesis. Clinical Pharmacy 1984;3:167-70. - PubMed
Patanwala 2010 {published data only}
    1. Patanwala AE, Amini R, Hays DP, Rosen P. Antiemetic therapy for nausea and vomiting in the emergency department. Journal of Emergency Medicine 2010;39(3):330-6. - PubMed
Poka 1993 {published data only}
    1. Poka R, Hernadi Z, Juhasz B, Lampe L. Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting. International Journal of Gynaecology and Obstetrics 1993;42:19-24. - PubMed
Richards 2011 {published data only}
    1. Richards JR, Richards IN, Ozery G, Derlet RW. Droperidol analgesia for opioid-tolerant patients. Journal of Emergency Medicine 2011;41(4):389-96. - PubMed
Roberts 1985 {published data only}
    1. Roberts WS, Wisniewski BJ, Cavanagh D, Marsden DE. Droperidol as an antiemetic in cis-platinum-induced nausea and vomiting. Oncology 1985;42:42-3. - PubMed
Sagae 2003 {published data only}
    1. Sagae S, Ishioka S, Fukunaka N, Terasawa K, Kobayashi K, Sugmara M, et al. Combination therapy with granisetron, methylprednisolone and droperidol as an antiemetic prophylaxis in CDDP-induced delayed emesis for gynaecologic cancer. Oncology 2003;64:46-53. - PubMed
Saller 1986 {published data only}
    1. Saller R, Hellenbrcht D. High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis. European Journal of Cancer and Clinical Oncology 1986;22(10):1199-203. - PubMed
Smith 2010 {published data only}
    1. Smith T, Paice J, Ritter J, Bobb B. An evidence-based approach to cutaneous treatment of nausea, pain and neuropathy in palliative care. Journal of Pain & Symptom Management 2010;39(2):372-3.
Smith 2011 {published data only}
    1. Smith T, Ritter JK, Coyne PJ, Parker GL, Dodson P, Fletcher DS. Testing the cutaneous absorption of lorazepam, diphenhydramine and haloperidol gel (ABH gel) used for cancer-related nausea. Journal of Clinical Oncology 2011;29(15 Suppl):1.
Smith 2012 {published data only}
    1. Smith T, Fletcher D, Coyne P, Ritter J, Dodson P, Parker G. ABH gel (Ativan, Benadryl, Diphenhydramine, Haloperidol, Haldol) is not absorbed from the skin of normal volunteers so cannot be effective against nausea. Journal of Pain & Symptom Management 2012;43:375-6. - PubMed
Stuart‐Harris 1983 {published data only}
    1. Stuart-Harris R, Buckman R, Starke I, Wiltshaw E. Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy. Postgraduate Medical Journal 1983;59:500-3. - PMC - PubMed
Thangathurai 2010 {published data only}
    1. Thangathurai D, Roffey P. Usefulness of droperidol as an anti-emetic in terminally ill cancer patients. Journal of Palliative Medicine 2010;13(8):939. - PubMed
Tramer 1999 {published data only}
    1. Tramer MR, Walder B. Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic review. Anesthesia and Analgesia 1999;88:1354-61. - PubMed
White 1992 {published data only}
    1. White RM, Myers EM, Ashayeri E, Gumbs RV, Pressoir R. Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics. American Journal of Clinical Oncology 1992;15(1):45-55. - PubMed
Yang 2011 {published data only}
    1. Yang LPH. Abiraterone acetate: in metastatic castration-resistant prostate cancer. Drugs 2011;71(15):2067-77. - PubMed

Additional references

Bentley 2001
    1. Bentley A, Boyd K. Use of clinical pictures in the management of nausea and vomiting. Palliative Medicine 2001;15:247-53. - PubMed
Carlisle 2006
    1. Carlisle J, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004125.pub2] - DOI - PMC - PubMed
Davis 2010
    1. Davis MP, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. Journal of Pain and Symptom Management 2010;39(4):756-67. - PubMed
Edmonds 2001
    1. Edmonds P, Karlsen S, Khan S, Addington-Hall J. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliative Medicine 2001;15:287-95. - PubMed
Food and Drug Administration 2001
    1. Important drug warning. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuma... 4 Dec 2001.
Glare 2004
    1. Glare P, Pereira G, Kristjanson L, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Supportive Care in Cancer 2004;12:432-40. - PubMed
Grande 2000
    1. Grande GE, Todd CJ. Why are trials in palliative care so difficult? Palliative Medicine 2000;14(1):69-74. - PubMed
Habib 2008
    1. Habib AS, Gan TJ. Pro: the Food and Drug Administration black box warning on droperidol is not justified. Anesthesia and Analgesia 2008;106:1414-7. - PubMed
Hadley 2009
    1. Hadley G, Derry S, Moore RA, Wee B. Can observational studies provide a realistic alternative to randomised controlled trials in palliative care? Journal of Pain & Palliative Care Pharmacotherapy 2009;23(2):106-13. - PubMed
Hirst 2001
    1. Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD003346] - DOI - PubMed
Jadad 1996
    1. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials 1996;17(1):1-12. - PubMed
Kao 2003
    1. Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Droperidol, QT prolongation, and sudden death: what is the evidence? Annals of Emergency Medicine 2003;41(4):546-8. - PubMed
Klinkenberg 2004
    1. Klinkenberg M, Willems DL, Wal G, Deeg DJH. Symptom burden in the last week of life. Journal of Pain and Symptom Management 2004;27:5-13. - PubMed
Ludwin 2008
    1. Ludwin DB, Shafer SL. Con: the black box warning on droperidol should not be removed (but should be clarified!). Anesthesia and Analgesia 2008;106:1418-20. - PubMed
Mannix 2004
    1. Mannix KA. Palliation of nausea and vomiting. In: Oxford Textbook of Palliative Medicine. Oxford University Press, 2004.
Martindale 2009
    1. Martindale. The complete drug reference. www.medicinescomplete.com/mc/martindale/current 2009 (accessed 3 February 2010).
McKeage 2006
    1. McKeage K, Simpson D, Wagstaff AJ. Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting. Drugs 2006;66(16):2123-47. - PubMed
MHRA 2001
    1. Medicines and Healthcare products Regulatory Agency. Discontinuation of Droleptan tablets, suspension and injection (droperidol). http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/... 11 January 2001.
MHRA 2008
    1. Medicines and Healthcare products Regulatory Agency. Marketing authorisations granted in January 2008. http://www.mhra.gov.uk/home/groups/l-reg/documents/licensing/con014139.pdf.
Nuttall 2007
    1. Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Shirk Marienau ME, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and Torsade de Pointes in the general surgical population? Anesthesiology 2007;107:531-6. - PubMed
Perkins 2009
    1. Perkins P, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006271.pub2] - DOI - PubMed
Rhodes 2001
    1. Rhodes VA, McDaniel RW. Nausea, vomiting and retching: complex problems in palliative care. CA: A Cancer Journal for Clinicians 2001;51:232-48. - PubMed
Twycross 1998
    1. Twycross R, Back I. Nausea and vomiting in advanced cancer. European Journal of Palliative Care 1998;5:39-45.
Wee 2008
    1. Wee B, Hadley G, Derry S. How useful are systematic reviews for informing palliative care practice? Survey of 25 Cochrane systematic reviews. BMC Palliative Care 2008;7:13. - PMC - PubMed

References to other published versions of this review

Dorman 2010
    1. Dorman S, Perkins P. Droperidol for treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews 2010, Issue 10. [DOI: 10.1002/14651858.CD006938.pub2] - DOI - PubMed

Publication types

LinkOut - more resources